# EDGAR Filing Document

**Accession Number:** 0001022899
**File Stem:** 0001641172-25-021552
**Filing Date:** 2025-7
**Character Count:** 9512
**Document Hash:** b5181cf2ab5b7e2e0a88274cb81d11a5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-021552.hdr.sgml**: 20250730

**ACCESSION NUMBER**: 0001641172-25-021552

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 16

**CONFORMED PERIOD OF REPORT**: 20250718

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250730

**DATE AS OF CHANGE**: 20250730

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Protagenic Therapeutics, Inc.\new
- **CENTRAL INDEX KEY:** 0001022899
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 061390025
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-12555
- **FILM NUMBER:** 251167389

**BUSINESS ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010
- **BUSINESS PHONE:** (212) 994-8200

**MAIL ADDRESS:**
- **STREET 1:** 149 FIFTH AVENUE
- **STREET 2:** SUITE 500
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10010

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Atrinsic, Inc.
- **DATE OF NAME CHANGE:** 20090630

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** NEW MOTION, INC.
- **DATE OF NAME CHANGE:** 20070504

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MPLC, Inc.
- **DATE OF NAME CHANGE:** 20050608

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

---

| | |
|:---|:---|
| **Date of Report (Date of Earliest Event Reported):** | **July 18, 2025** |

---

---

| |
|:---|
| **PROTAGENIC THERAPEUTICS, INC.**<br> **** |
| (Exact name of Company as specified in its charter) |

---

<u>Delaware</u> <u>001-12555</u> <u>06-1390025</u> <br> (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

<u>149 Fifth Avenue, Suite 500, New York, NY</u> <u>10010</u> <br> (Address of principal executive offices) (Zip Code)

<u>212-994-8200</u> <br> (Company's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Ticker symbol(s) | Name of each exchange on which registered |
| Common Stock | PTIX | Nasdaq |
| Common Stock Warrants | PTIXW | Nasdaq |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01 Regulation FD Disclosure.**

On July 30, 2025, Protagenic Therapeutics, Inc (the "Company") issued a press release announcing that the Company was granted a new patent in Japan for its modified stilbenoid program drug candidates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

**Item 9.01 Financial Statements and Exhibits.**

*(d) Exhibits*

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1 | [Press Release issued July 30 2025, furnished herewith.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document. |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Protagenic Therapeutics, Inc.** | **Protagenic Therapeutics, Inc.** |
| Date: July 30, 2025 | By: | */s/ Barrett Evans* |
|  |  | Barrett Evans |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

**FOR IMMEDIATE RELEASE**

 ****

***Protagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug Candidates***

**NEW YORK, NY and SANTA BARBARA, CA, July 30, 2025**

Protagenic Therapeutics, Inc. (Nasdaq: PTIX) (the "Company") today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP 7714571B, a patent which runs until March 31, 2041. This patent underpins one of the Company's key pipeline assets, a modified stilbenoid, and importantly provides the Company with exclusivity to particular compounds *per se,* formulations containing a number of drug candidates, and their medical use, which is to treat epilepsy and seizures.

Colin Stott, Chief Operating Officer of Protagenic Therapeutics, Inc. said:

*"We are delighted to announce the grant of this important patent for the Company in Japan. Such a grant builds on the previous grant of the same patent in the UK (Patent GB2609814), and demonstrates the ability of the Company to continue its innovative approach and to add value and important protection to its development pipeline for shareholders. We anticipate being able to expand the grant of this patent in other territories in the future."* 

 

**About the Japanese Pharmaceutical Market<sup>1,2</sup>**

The Japanese pharmaceutical market is the world's third largest pharmaceutical market. In 2025, the Japanese pharmaceutical market is worth more than $85 billion US dollars, and the market size is anticipated to reach $93 billion US dollars by 2030.

**About the Global Epilepsy Drug Market<sup>3</sup>**

The global epilepsy drug market size was expected to be valued at USD $11.29 billion in 2024 and is anticipated to reach around USD $18.74 billion by 2034, expanding at a CAGR of 5.20% over the forecast period from 2025 to 2034.

**References**

**1)** **<u>https://www.trade.gov/country-commercial-guides/japan-pharmaceuticals</u>**

**2)** **<u>https://www.mordorintelligence.com/industry-reports/japan-pharmaceutical-market</u>**

**3)** **<u>https://www.precedenceresearch.com/epilepsy-drug-market</u>**

**About Protagenic Therapeutics, Inc.**

Protagenic Therapeutics (Nasdaq: PTIX) is pioneering novel treatments across a range of therapeutic areas. For more information, visit <u>www.protagenic.com</u>.

**Forward-Looking Statements**

Statements in this press release contain "forward-looking statements," within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "suggest," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including risks related to the completion, timing and results of current and future clinical studies relating to the Company's product candidates. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.

**Company Contact:**

Alexander K. Arrow, MD, CFA

Chief Financial Officer

Protagenic Therapeutics, Inc.

149 Fifth Ave, Suite 500, New York, NY 10010

Tel: 213-260-4342<br> Email: <u>alex.arrow@protagenic.com</u>